While these mechanistic insights have provided valuable information about HOXA regulation in MLL-rearranged AML, this molecular subtype accounts for <5% of all AML patients and only 25% of AMLs that express HOXA genes [1]. This evidence concerns the gene KMT2A and acute myeloid leukemia.